RxDoctor Payments DataLook up a doctor →

Asadulla Mohammed, MD

Pulmonary Disease · Berkley, MINPI 1508819350

Payments from drug & device makers

$91,386in general payments, 2019–2025

Across 978 payments — averaging $93.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$74K
  • AstraZeneca$2K
  • GSK$2K
  • Boehringer Ingelheim$2K
  • Mylan Specialty L.p.$1K
  • Inspire Medical Systems, Inc.$954
  • plus $9K from 42 others

What the payments were for

  • Speaking & faculty fees$69,90076%
  • Travel & lodging$2,2122%
  • Food & beverage$18,94721%
  • Education$3260%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$91,386 in reported general payments places this provider in the 90th percentile of 463 pulmonary disease providers in Michigan.

See all pulmonary disease providers in Michigan

Medicare billing

Part B allowed, 2024
$495,495
Medicare patients
803
Services billed
6,805

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate27$359,850
Trelegy ElliptaFluticasone/Umeclidin/Vilanter274$214,215
GlassiaAlpha-1-Proteinase Inhibitor13$192,748
OpsumitMacitentan12$154,086
Breztri AerosphereBudesonide/Glycopyr/Formoterol151$119,981
Dupixent SyringeDupilumab26$96,823
Dupixent PenDupilumab25$93,639
TezspireTezepelumab-Ekko21$89,517
Prolastin CAlpha-1-Proteinase Inhibitor12$74,923
Spiriva RespimatTiotropium Bromide65$49,261
Breo ElliptaFluticasone/Vilanterol67$34,559
Stiolto RespimatTiotropium Br/Olodaterol Hcl35$18,452
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate56$15,442
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr25$14,655
Spiriva HandihalerTiotropium Bromide16$11,803

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$1,572$427,562127 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$1,881$270,899380 claims
AstraZenecaBreztri Aerosphere, Tezspire, Symbicort$2,218$215,205199 claims
Takeda Pharmaceuticals U.S.A., Inc.Glassia$538$192,74813 claims
Actelion Pharmaceuticals US, Inc.Opsumit$74,347$154,08612 claims
Grifols USA, LLCProlastin C$744$74,92312 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$217$3,89513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 463 pulmonary disease providers in Michigan.

Other pulmonary disease in Berkley

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →